JP2024515319A5 - - Google Patents

Info

Publication number
JP2024515319A5
JP2024515319A5 JP2023566450A JP2023566450A JP2024515319A5 JP 2024515319 A5 JP2024515319 A5 JP 2024515319A5 JP 2023566450 A JP2023566450 A JP 2023566450A JP 2023566450 A JP2023566450 A JP 2023566450A JP 2024515319 A5 JP2024515319 A5 JP 2024515319A5
Authority
JP
Japan
Prior art keywords
car
cells
tumor
nucleic acid
expression vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515319A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/090106 external-priority patent/WO2022228538A1/zh
Publication of JP2024515319A publication Critical patent/JP2024515319A/ja
Publication of JP2024515319A5 publication Critical patent/JP2024515319A5/ja
Pending legal-status Critical Current

Links

JP2023566450A 2021-04-30 2022-04-29 免疫調節因子を発現するcarベクター及びその応用 Pending JP2024515319A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110481979 2021-04-30
CN202110481979.9 2021-04-30
PCT/CN2022/090106 WO2022228538A1 (zh) 2021-04-30 2022-04-29 一种表达免疫调节因子的car载体及其应用

Publications (2)

Publication Number Publication Date
JP2024515319A JP2024515319A (ja) 2024-04-08
JP2024515319A5 true JP2024515319A5 (cg-RX-API-DMAC7.html) 2025-04-17

Family

ID=82862040

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566450A Pending JP2024515319A (ja) 2021-04-30 2022-04-29 免疫調節因子を発現するcarベクター及びその応用

Country Status (6)

Country Link
US (1) US20240325442A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024515319A (cg-RX-API-DMAC7.html)
CN (1) CN114934071B (cg-RX-API-DMAC7.html)
AU (1) AU2022263746A1 (cg-RX-API-DMAC7.html)
GB (1) GB2621770B (cg-RX-API-DMAC7.html)
WO (1) WO2022228538A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117986387A (zh) * 2023-05-31 2024-05-07 四川大学华西医院 一种新型小型化car设计及制备方法和应用
CN119220499B (zh) * 2023-11-24 2025-11-25 成都赛恩吉诺生物科技有限公司 表达gm-csf的非连续截短功能区的免疫工程细胞及应用
CN119144565B (zh) * 2023-11-24 2025-11-25 成都赛恩吉诺生物科技有限公司 表达GM-CSF的exon 2功能区的免疫工程细胞及应用
CN119144564B (zh) * 2023-11-24 2025-11-25 成都赛恩吉诺生物科技有限公司 表达GM-CSF的Ahelix功能区的免疫工程细胞及应用
CN119144563B (zh) * 2023-11-24 2025-11-25 成都赛恩吉诺生物科技有限公司 表达gm-csf截短功能区片段的免疫工程细胞及应用
CN119432754B (zh) * 2023-11-24 2025-10-10 成都赛恩吉诺生物科技有限公司 表达gm-csf的连续截短功能区的免疫工程细胞及应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2868121C (en) * 2012-03-23 2021-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
WO2015188141A2 (en) * 2014-06-06 2015-12-10 Memorial Sloan-Kettering Cancer Ceneter Mesothelin-targeted chimeric antigen receptors and uses thereof
JP7032304B2 (ja) * 2015-07-28 2022-03-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア キメラ抗原受容体を発現する改変された単球/マクロファージおよびその使用
CN105505869A (zh) * 2015-12-21 2016-04-20 河南大学淮河医院 一种针对肿瘤干细胞的嵌合抗原受体t细胞
US20180028631A1 (en) * 2016-07-29 2018-02-01 Lan Bo Chen Anti-ssea4 chimeric antigen receptors and their use for treating cancer
CN106543288A (zh) * 2016-10-24 2017-03-29 山东兴瑞生物科技有限公司 一种间皮素嵌合抗原受体修饰的t细胞制备及胰腺癌治疗上的应用
EP3710470A4 (en) * 2017-11-14 2021-07-28 Memorial Sloan-Kettering Cancer Center IL-33 SECRETING IMMUNE RESPONSIBLE CELLS AND USES
AU2018367452B2 (en) * 2017-11-14 2024-06-13 Memorial Sloan-Kettering Cancer Center IL-36 secreting immunoresponsive cells and uses thereof
EP3766977A4 (en) * 2018-03-16 2021-12-08 Shinshu University GENETICALLY MODIFIED CELL AND METHOD FOR MANUFACTURING IT
US20210214723A1 (en) * 2018-06-01 2021-07-15 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
US20220000921A1 (en) * 2018-11-20 2022-01-06 Innovative Cellular Therapeutics Holdings, Ltd. Modified Cell Expressing Therapeutic Agent and Uses thereof
CN110760001B (zh) * 2019-07-29 2023-03-24 浙江启新生物技术有限公司 Gm-csf敲低及其中和单链抗体分泌的嵌合抗原受体t细胞构建与应用
CN110396131B (zh) * 2019-08-23 2020-07-10 北京鼎成肽源生物技术有限公司 一种ErbB2单链抗体、靶向人ErbB2的嵌合抗原受体、重组载体、重组细胞和应用
CN110964121B (zh) * 2019-12-20 2022-09-16 山东省齐鲁细胞治疗工程技术有限公司 一种分泌il-7、il-15因子的cd19-car-t细胞及其应用
CN111944760A (zh) * 2020-08-14 2020-11-17 广东先康达生物科技有限公司 一种分泌双特异性抗体的免疫细胞及其应用
CN112210018A (zh) * 2020-10-12 2021-01-12 广东昭泰体内生物医药科技有限公司 一种靶向gpc3的嵌合抗原受体及其应用

Similar Documents

Publication Publication Date Title
Kirkwood et al. Immunotherapy of cancer in 2012
Li et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself
Xiang et al. A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice
Whiteside et al. Emerging opportunities and challenges in cancer immunotherapy
Kazemi et al. Immunotherapeutic approaches for cancer therapy: an updated review
Janke et al. Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy
Fuse et al. Recall responses by helpless memory CD8+ T cells are restricted by the up-regulation of PD-1
US12491201B2 (en) Maximizing T-cell memory and compositions and methods therefor
JP2021530217A5 (cg-RX-API-DMAC7.html)
JP2019500894A5 (cg-RX-API-DMAC7.html)
JP2025185014A (ja) 治療用分子のt細胞送達のための組成物および方法
Yu et al. Combinational immunotherapy with Allo-DRibble vaccines and anti-OX40 co-stimulation leads to generation of cross-reactive effector T cells and tumor regression
Junghans The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective
JP2023500338A5 (cg-RX-API-DMAC7.html)
JP2019507582A5 (cg-RX-API-DMAC7.html)
JP7812549B2 (ja) 人工免疫監視キメラ抗原受容体(ai-car)及びそれを発現する細胞
Ji et al. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines
Chen et al. IL-21-and CXCL9-engineered GPC3-specific CAR-T cells combined with PD-1 blockade enhance cytotoxic activities against hepatocellular carcinoma
Gu et al. Forced co-expression of IL-21 and IL-7 in whole-cell cancer vaccines promotes antitumor immunity
Zhao et al. Vaccines targeting tumor blood vessel antigens promote CD8+ T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice
JP2022528024A5 (cg-RX-API-DMAC7.html)
Sharma et al. SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model
Xu et al. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma
Asgari et al. In vitro cytotoxic effect of Trastuzumab in combination with Pertuzumab in breast cancer cells is improved by interleukin-2 activated NK cells
CN121969385A (zh) 含有il-2变体以增强car t细胞的功能性的car-衔接子